AngioDynamics (NASDAQ:ANGO) Releases FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of -0.340–0.310 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of $285.0 million-$288.0 million, compared to the consensus revenue estimate of $284.9 million. AngioDynamics also updated its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Trading Up 2.9 %

Shares of NASDAQ ANGO opened at $9.66 on Wednesday. The company has a market capitalization of $390.90 million, a price-to-earnings ratio of -1.72 and a beta of 0.56. AngioDynamics has a twelve month low of $5.47 and a twelve month high of $13.50. The business has a 50 day simple moving average of $10.30 and a 200-day simple moving average of $8.84.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the prior year, the company earned ($0.05) earnings per share. The firm’s revenue was down .1% compared to the same quarter last year. As a group, equities analysts predict that AngioDynamics will post -0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lifted their target price on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

Insider Transactions at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now directly owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.40% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.